Top

Published in:

01-06-2012 | Effects of Standard of Art Treatment

Changes in neurocognitive functioning and quality of life in adult patients with brain tumors treated with radiotherapy

Authors: Silvia Scoccianti, Beatrice Detti, Samantha Cipressi, Alberto Iannalfi, Ciro Franzese, Giampaolo Biti

Published in: Journal of Neuro-Oncology | Issue 2/2012

Abstract

This review aims to summarize what is currently known about neurocognitive outcome and quality of life in patients with brain tumors treated with radiotherapy. Whether potential tumor-controlling benefits of radiotherapy outweigh its potential toxicity in the natural history of brain tumors is a matter of debate. This review focuses on some of the adult main brain tumors, for which the issue of neurocognitive decline has been thoroughly studied: low-grade gliomas, brain metastases, and primary central nervous system lymphomas. The aims of this review are: (1) the analysis of existing data regarding the relationship between radiotherapy and neurocognitive outcome; (2) the identification of strategies to minimize radiotherapy-related neurotoxicity by reducing the dose or the volume; (3) the evidence-based data concerning radiotherapy withdrawal; and (4) the definition of patients subgroups that could benefit from immediate radiotherapy. For high grade gliomas, the main findings from literature are summarized and some strategies to reduce the neurotoxicity of the treatment are presented. Although further prospective studies with adequate neuropsychological follow-up are needed, this article suggests that cognitive deficits in patients with brain tumor have a multifactorial genesis: radiotherapy may contribute to the neurocognitive deterioration, but the causes of this decline include the tumor itself, disease progression, other treatment modalities and comorbidities. Treatment variables, such as total and fractional dose, target volume, and irradiation technique can dramatically affect the safety of radiotherapy: optimizing radiation parameters could be an excellent approach to improve outcome and to reduce neurotoxicity. At the same time, delayed radiotherapy could be a valid option for highly selected patients.

Liu R, Page M, Solheim K, Fox S, Chang SM (2009) Quality of life in adults with brain tumors: current knowledge and future directions. Neuro Oncol 11:330–339PubMedCrossRef

Meyers CA, Wefel JS (2003) The use of the mini-mental status examination to assess cognitive functioning in cancer trials: no ifs, ands, buts or sensitivity. J Clin Oncol 21:3557–3558PubMedCrossRef

Keime-Guibert F, Napolitano M, Delattre JY (1998) Neurological complications of radiotherapy and chemotherapy. J Neurol 245:695–708PubMedCrossRef

Laack NN, Brown PD, Ivnik RJ et al (2005) Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys 63:1175–1183PubMedCrossRef

Douw L, Klein M, Fagel SS et al (2002) Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8:810–818CrossRef

Taphoorn MJ (2009) Neurocognitive effects of radiotherapy. American Society Clinical Oncology Annual Meeting, Educational book manuscript, pp 90–93

Klein M, Heimans JJ, Aaronson NK et al (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360:1361–1368PubMedCrossRef

Klein M, Engelberts NH, van der Ploeg HM et al (2003) Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 54:514–520PubMedCrossRef

Reijneveld JC, Stitskoorn MM, Klein M et al (2001) Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. Neurology 56:618–623PubMedCrossRef

10.

Brown PD, Buckner JC, Uhm JH, Shaw EG (2003) The neurocognitive effects of radiation in adult low-grade glioma patients. Neuro Oncol 5:161–167PubMedCrossRef

11.

Lesser GJ (2001) Chemotherapy of low -grade gliomas. Semin Radiat Oncol 11:138–144PubMedCrossRef

12.

Olson JD, Riedel E, DeAngelis LM (2000) Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54:1442–1448PubMedCrossRef

13.

Surma-aho O, Niemelä M, Vilkki J et al (2001) Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 56:1285–1290PubMedCrossRef

14.

Postma TJ, Klein M, Verstappen CC et al (2002) Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma. Neurology 59:121–123PubMedCrossRef

15.

Correa DD, Shi W, Thaler HT, Cheung AM, DeAngelis LM, Abrey LE (2008) Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol 86:321–327PubMedCrossRef

16.

Vigliani MC, Sichez N, Poisson M, Delattre JY (1996) A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int J Radiat Oncol Biol Phys 35:527–533PubMedCrossRef

17.

Armstrong CL, Hunter JV, Ledakis GE et al (2002) Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology 59:40–48PubMedCrossRef

18.

Brown PD, Buckner JC, O’Fallon JR et al (2003) Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 21:2519–2524PubMedCrossRef

19.

Torres IJ, Mundt AJ, Sweeney PJ et al (2003) A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors. Neurology 60:1113–1118PubMed

20.

Kiebert GM, Curran D, Aaronson NK et al (1998) Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomized phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer 34:1902–1908PubMedCrossRef

21.

Karim AB, Maat B, Hatlevoll R et al (1996) A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36:549–556PubMedCrossRef

22.

Shaw E, Arusell R, Scheithauer B et al (2002) Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study. J Clin Oncol 20:2267–2276PubMedCrossRef

23.

Thornton AF Jr, Hegarty TJ, Ten Haken RK et al (1991) Three dimensional treatment planning of astrocytomas: a dosimetric study of cerebral irradiation. Int J Radiat Oncol Biol Phys 20:1309–1315PubMedCrossRef

24.

Gregor A, Cull A, Traynor E, Stewart M, Lander F, Love S (1996) Neuropsychometric evaluation of long-term survivors of adult brain tumours: relationship with tumour and treatment parameters. Radiother Oncol 41:55–59PubMed

25.

Taphoorn MJ, Klein M (2004) Cognitive deficits in adult patients with brain tumours. Lancet Neurol 3:159–168PubMedCrossRef

26.

Schiff D, Brown PD, Giannini C (2007) Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 69:1366–1373PubMedCrossRef

27.

van den Bent MJ, Afra D, de Witte O et al (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985–990PubMedCrossRef

28.

Lote K, Egeland T, Hager B et al (1997) Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol 15:3129–3140PubMed

29.

Pignatti F, van den Bent M, Curran D et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–2084PubMedCrossRef

30.

Daniels TB, Brown PD, Felten SJ (2011) Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys 1:218–224CrossRef

31.

Shaw EG, Berkey B, Coons SW et al (2008) Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg 109:835–841PubMedCrossRef

32.

Meyers CA, Smith JA, Bezjak A et al (2004) Neurocognitive function and progression in patients with brain metastases treated with whole brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22:157–165PubMedCrossRef

33.

Regine WF, Scott C, Murray K, Curran W (2001) Neurocognitive outcome in brain metastases patients treated with accelerated fractionation vs. accelerated hyperfractionationated radiotherapy: an analysis from radiation therapy group study 91-04. Int J Radiat Oncol Biol Phys 51:711–717PubMedCrossRef

34.

Aoyama H, Tago M, Kato N et al (2007) Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68:1388–1395PubMedCrossRef

35.

Chang EL, Wefel JS, Hess KR et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole brain irradiation: a randomized controlled trial. Lancet Oncol 10:1037–1044PubMedCrossRef

36.

Graham PH, Bucci J, Browne L (2010) Randomized comparison of whole brain radiotherapy, 20 Gy in four daily fractions versus 40 Gy in 20 twice-daily fractions, for brain metastases. Int J Radiat Oncol Biol Phys 77:648–654PubMedCrossRef

37.

Soffietti R, Mueller M, Abacioglu S et al (2010) Quality of life results of an EORTC phase III randomized trial of adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases of solid tumors. J Clin Oncol 28:15s

38.

Scott C, Suh J, Stea B, Nabid A, Hackman J (2007) Improved survival, quality of life and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole radiation therapy for brain metastases. Am J Clin Oncol 30:580–587PubMedCrossRef

39.

Ahles TA, Saykin AJ, Furstenberg CT et al (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493PubMedCrossRef

40.

Soussain C, Ricard D, Fike JR et al (2009) CNS complications of radiotherapy and chemotherapy. Lancet 374:1639–1651PubMedCrossRef

41.

Vardy J, Wefel JS, Ahles T et al (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 19:623–629PubMedCrossRef

42.

Patchell RA, Tibbs PA, Regine WF et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain. A randomized trial. JAMA 280:1485–1489PubMedCrossRef

43.

Kocher M, Soffietti R, Abacioglu U et al (2011) Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of 1–3 cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29:134–141PubMedCrossRef

44.

Roos DE, Wirth A, Burmeister BH et al (2006) Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiother Oncol 80:318–322PubMedCrossRef

45.

Aoyama H, Shirato H, Tago M et al (2006) Stereotactic radiosurgery plus whole brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases. A randomized controlled trial. JAMA 295:2483–2491PubMedCrossRef

46.

Li J, Bentzen SM, Renschler M et al (2007) Regression after whole brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 25:1260–1266PubMedCrossRef

47.

Khuntia D, Brown P, Li J, Mehta M (2006) Whole brain radiotherapy in the management of brain metastases. J Clin Oncol 24:1295–1304PubMedCrossRef

48.

Borgelt B, Gelber R, Larson M, Hendrickson F, Griffin T, Roth R (1981) Ultra-rapid high dose irradiation for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7:1633–1638PubMedCrossRef

49.

Tofilon PJ, Fike JR (2000) The radioresponse of the central nervous system: a dynamic process. Radiat Res 153:357–370PubMedCrossRef

50.

Monje ML, Palmer T (2003) Radiation injury and neurogenesis. Curr Opin Neurol 16:129–134PubMedCrossRef

51.

Shors TJ, Miesagaes G, Beylin A, Whao M, Rydel T, Gould E (2001) Neurogenesis in the adult is involved in the formation of trace memories. Nature 410:372–376PubMedCrossRef

52.

Byrne TN (2005) Cognitive sequelae of brain tumor treatment. Curr Opin Neurol 18:662–666PubMedCrossRef

53.

Rola R, Raber J, Rizk A et al (2004) Radiation-induced impairment of hippocampal neurogenesis is associated with cognitive deficits in young mice. Exp Neurol 188:316–330PubMedCrossRef

54.

Gondi V, Tomè WA, Marsh J et al (2010) Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol 95:327–331PubMedCrossRef

55.

Weitzner MA, Meyers CA, Valentine AD (1995) Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 7:347–350PubMed

56.

Chan AS, Cheung MC, Law SC et al (2004) Phase II study of alpha-tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer 100:398–404PubMedCrossRef

57.

Shaw EG, Rosdhal R, D’Agostino RB et al (2006) Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 24:1415–1420PubMedCrossRef

58.

Robbins ME, Zhao W, Garcia-Espinosa MA, Diz DI (2010) Renin-angiotensin system blockers and modulation of radiation-induced brain injury. Curr Drug Targets 11:1413–1422PubMed

59.

Sawrie SM, Guthrie BL, Spencer SA, Nordal RA, Meredith RF, Markert JM, Cloud GA, Fiveash JB (2008) Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int J Radiat Oncol Biol Phys 70:181–186PubMedCrossRef

60.

Gaspar L, Scott C, Rotman M et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751PubMedCrossRef

61.

Abrey LE, DeAngelis LM, Yahalom J (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16:859–863PubMed

62.

Bessell EM, López-Guillermo A, Villá S et al (2002) Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20:231–236PubMedCrossRef

63.

Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570–4574PubMedCrossRef

64.

Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18:3144–3150PubMed

65.

Lai R, Abrey LE, Rosenblum MK, DeAngelis LM (2004) Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 62:451–456PubMedCrossRef

66.

O’Brien PC, Roos DE, Pratt G et al (2006) Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys 64:408–413PubMedCrossRef

67.

Correa DD, Rocco-Donovan M, DeAngelis LM et al (2009) Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol 91:315–321PubMedCrossRef

68.

Abrey LE, Correa DD (2005) Treatment-related neurotoxicity. Hematol Oncol Clin N Am 19:729–738CrossRef

69.

Fisher B, Seiferheld W, Schultz C et al (2005) Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol 74:201–205PubMedCrossRef

70.

Ferreri AJ, Reni M, Pasini F et al (2002) A multicenter study of treatment of primary CNS lymphoma. Neurology 58:1513–1520PubMedCrossRef

71.

DeAngelis LM, Seiferheld W, Schold SC et al (2002) Combination chemotherapy and radiotherapy for primary central nervous lymphoma. Radiation Therapy Oncology Group 93–100. J Clin Oncol 21:4643–4648CrossRef

72.

Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H et al (2003) High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21:4483–4488PubMedCrossRef

73.

Harder H, Holtel H, Bromberg JE et al (2004) Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62:544–547PubMedCrossRef

74.

Montemurro M, Kiefer T, Schüler F et al (2007) Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 18:665–671PubMedCrossRef

75.

Ferreri AJ, Reni M, Foppoli M et al (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512–1520PubMedCrossRef

76.

Shibamoto Y, Hayabuchi N, Hiratsuka J et al (2003) Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer 97:128–133PubMedCrossRef

77.

Thiel E, Korfel A, Martus P et al (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036–1047PubMedCrossRef

78.

Shaw EG, Wang M, Coons S et al (2006) 2008) Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: radiation therapy (RT) versus RT+ procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). J Clin Oncol 26:15S

79.

Henriksson R, Asklund T, Poulsen HS (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol 104:639–646PubMedCrossRef

80.

Corn BW, Wang M, Fox S et al (2009) Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03. J Neurooncol 95:247–257PubMedCrossRef

81.

Archibald YM, Lunn D, Ruttan LA et al (1994) Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 80:247–253PubMedCrossRef

82.

Hottinger AF, Yoon H, DeAngelis LM, Abrey LE (2009) Neurological outcome of long-term glioblastoma survivors. J Neurooncol 95:301–305PubMedCrossRef

83.

Veilleux N, Goffaux P, Boudrias M et al (2010) Quality of life in neurooncology-age matters. J Neurosurg 113:325–332PubMedCrossRef

84.

Klein M, Taphoorn MJ, Heimans JJ et al (2001) Neurobehavioral status and health-related quality of life in newly diagnosed high grade glioma patients. J Clin Oncol 19:4037–4047PubMed

85.

Talacchi A, Santini B, Savazzi S, Gerosa M (2011) Cognitive effects of tumour and surgical treatment in glioma patients. J Neurooncol 103:541–549PubMedCrossRef

86.

Taphoorn MJ, van den Bent MJ, Mauer ME et al (2007) Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol 25:5723–5730PubMedCrossRef

87.

Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593PubMedCrossRef

88.

Bosma I, Vos MJ, Heimans JJ et al (2007) The course of neurocognitive functioning in high-grade glioma patients. Neuro Oncol 9:53–62PubMedCrossRef

89.

Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535PubMedCrossRef

90.

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef

91.

Taphoorn MJ, Stupp R, Coens C et al (2005) Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6:937–944PubMedCrossRef

92.

Trojanowski T, Peszyński J, Turowski K et al (1989) Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy. J Neurosurg 70:18–23PubMedCrossRef

93.

Henriksson R, Malmström A, Bergström P et al (2006) High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. J Neurooncol 78:321–326PubMedCrossRef

94.

Osoba D, Brada M, Yung WK, Prados M (2000) Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18:1481–1491PubMed

95.

Wang M, Cairncross G, Shaw E et al (2010) Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: Radiation Therapy Oncology Group trial 9402. Int J Radiat Oncol Biol Phys 77:662–669PubMedCrossRef

96.

Hassler MR, Elandt K, Preusser M et al (2010) Neurocognitive training in patients with high-grade glioma: a pilot study. J Neurooncol 97:109–115PubMedCrossRef

Title: Changes in neurocognitive functioning and quality of life in adult patients with brain tumors treated with radiotherapy
Authors: Silvia Scoccianti
Beatrice Detti
Samantha Cipressi
Alberto Iannalfi
Ciro Franzese
Giampaolo Biti
Publication date: 01-06-2012
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2012
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-012-0821-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Changes in neurocognitive functioning and quality of life in adult patients with brain tumors treated with radiotherapy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Factors affecting the cerebral network in brain tumor patients

Lessons from traumatic head injury for assessing functional status after brain tumour

Agnosias: recognition disorders in patients with brain tumors

Cognitive outcome as part and parcel of clinical outcome in brain tumor surgery

Reconsidering outcomes that matter to patients

The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors